CLINICAL POTENTIAL OF FLOW CYTOMETRY--HEAD & NECK CANCER

流式细胞术的临床潜力--Head

• 批准号: 3423378
• 负责人: JOHN F ENSLEY
• 金额: $ 7.25万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-09-30 至 1993-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3423378
• 关键词: cellular oncology; combination cancer therapy; diploidy; flow cytometry; head /neck neoplasm; human subject; human therapy evaluation; immunofluorescence technique; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer genetics; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; neoplastic cell; prognosis; squamous cell carcinoma

Squamous cell carcinomas of the head and neck (SCCHN) are one of the two most common human cancers. Most patients present with disease that is incurable or likely to fail conventional therapy. Unacceptable functional and cosmetic deficits occur in many when cured with surgery and/or radiotherapy. Effective cytotoxic therapy has the potential to cure patients with advanced disease (induction trials), reduce the undesirable consequences of conventional therapy (organ preservation trials) and prevent recurrences following conventional therapy (adjuvant trials). Cytotoxic therapy has shown such potential only when microscopic disease is eradicated. Clinical trials are hampered by widely different cytotoxic responses or clinical outcomes following conventional therapy in patients with similar clinical characteristics and amount of disease. Attempts to predict the clinical outcome of individual patients on the basis of differences in clinical or morphological parameters have not been successful. Flow cytometric measurements of cellular DNA content have been associated with prognostic differences in many human malignancies. Comparisons of DNA ploidy in recurrent and previously untreated patients as well as serial measurements in advanced patients undergoing cytotoxic therapy indicate that patients with diploid tumors or significant subpopulations do not achieve microscopic eradication of tumor. In advanced patients undergoing surgery as initial therapy, advantages in recurrence rates, disease free survival and absolute survival have been associated with diploid tumors. Significant differences in the histological patterns if tumor growth and stromal interface for diploid and aneuploid tumors have been demonstrated and may account for the differences in local-regional relapse rates following surgery. The interpretation and clinical application of these findings is difficult and incomplete, particularly for diploid tumors or components of mixed tumors, without further characterization of these ploidy groups by multi-parameter flow cytometry. The determination of cellular DNA content parameters may aid in the prediction of clinical outcome and indicate mechanisms underlying response and resistance in patients with advanced SCCHN.

头颈部鳞状细胞癌（SCCHN）是两种常见的恶性肿瘤之一。 最常见的人类癌症 大多数患者的疾病是 无法治愈或可能无法通过常规治疗。 不可接受 许多患者在手术治愈后会出现功能和外观缺陷 和/或放射疗法。 有效的细胞毒疗法有可能 治愈晚期疾病患者（诱导试验），减少 常规治疗的不良后果（器官保存 试验），并防止复发后，常规治疗（辅助 审判）。 细胞毒性治疗只有在以下情况下才显示出这种潜力： 微生物疾病被根除。 临床试验受到阻碍， 广泛不同的细胞毒性反应或临床结果， 具有相似临床特征的患者的常规治疗 疾病的数量。 试图预测的临床结果 根据患者的临床或 形态学参数尚未成功。 流式细胞术 细胞DNA含量的测量与预后相关， 许多人类恶性肿瘤的差异。 DNA倍性比较 复发和既往未治疗的患者以及连续 在接受细胞毒性治疗的晚期患者中的测量结果表明， 患有二倍体肿瘤或重要亚群的患者则没有 实现肿瘤的显微根除。 晚期患者 接受手术作为初始治疗，复发率方面的优势， 无病生存率和绝对生存率与 二倍体肿瘤 如果出现以下情况， 二倍体和非整倍体肿瘤的肿瘤生长和基质界面， 已被证明，并可能占当地区域的差异， 术后复发率。 解释和临床 这些发现的应用是困难和不完整的，特别是 对于二倍体肿瘤或混合肿瘤的组分，不需要进一步 通过多参数流对这些倍性组的表征 细胞仪 细胞DNA含量参数的测定可能有助于 在临床结果的预测，并指出潜在的机制 晚期SCCHN患者的反应和耐药性。